- Home
- ABSI vs ALDX Comparison
ABSI vs ALDX Comparison
Compare ABSI & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- ALDX
- Stock Information
- Founded
- ABSI 2011
- ALDX 2004
- Country
- ABSI United States
- ALDX United States
- Employees
- ABSI N/A
- ALDX N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- ALDX Health Care
- Exchange
- ABSI Nasdaq
- ALDX Nasdaq
- Market Cap
- ABSI 338.0M
- ALDX 342.3M
- IPO Year
- ABSI 2021
- ALDX 2014
- Fundamental
- Price
- ABSI $2.62
- ALDX $5.09
- Analyst Decision
- ABSI Strong Buy
- ALDX Strong Buy
- Analyst Count
- ABSI 5
- ALDX 2
- Target Price
- ABSI $7.98
- ALDX $9.50
- AVG Volume (30 Days)
- ABSI 4.1M
- ALDX 776.7K
- Earning Date
- ABSI 11-11-2025
- ALDX 11-06-2025
- Dividend Yield
- ABSI N/A
- ALDX N/A
- EPS Growth
- ABSI N/A
- ALDX N/A
- EPS
- ABSI N/A
- ALDX N/A
- Revenue
- ABSI $4,138,000.00
- ALDX N/A
- Revenue This Year
- ABSI $44.71
- ALDX N/A
- Revenue Next Year
- ABSI $374.26
- ALDX $63.48
- P/E Ratio
- ABSI N/A
- ALDX N/A
- Revenue Growth
- ABSI 27.32
- ALDX N/A
- 52 Week Low
- ABSI $2.01
- ALDX $1.14
- 52 Week High
- ABSI $6.33
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- ABSI 49.98
- ALDX 37.78
- Support Level
- ABSI $2.37
- ALDX $5.48
- Resistance Level
- ABSI $2.89
- ALDX $5.88
- Average True Range (ATR)
- ABSI 0.15
- ALDX 0.29
- MACD
- ABSI 0.03
- ALDX -0.10
- Stochastic Oscillator
- ABSI 52.63
- ALDX 10.63
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.